Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
J Gastroenterol Hepatol. 2019 Jul;34(7):1214-1221. doi: 10.1111/jgh.14537. Epub 2018 Nov 28.
Portal vein tumor thrombus (PVTT) predicts a poor prognosis in hepatocellular carcinoma (HCC) patients. Platelets (PLTs) play an important role in HCC progression and metastasis. However, the relationship between PLTs and PVTT remains unclear. This study aimed to evaluate the value of PLT counts in the prognosis of HCC patients with PVTT after hepatectomy.
From January 2002 to December 2012, 694 HCC patients with PVTT after hepatectomy were evaluated. The patients were divided into the thrombocytopenia group (PLT < 100 × 10 /L), the normal group, and the thrombocytosis group (PLT > 300 × 10 /L) based on the preoperative PLT level. A propensity score matching (PSM) analysis was used.
Before the PSM, PVTT patients with thrombocytopenia exhibited longer recurrence-free survival (RFS) and overall survival (OS) compared with those with normal PLT counts (both P < 0.001) or thrombocytosis (P = 0.008 and P = 0.046). For the thrombocytopenia group and the normal group, the 1-, 2-, and 3-year RFS values were 30.0%, 17.6%, and 15.7% and were 10.8%, 6.6%, and 5.8% (P < 0.001), respectively; the 1-, 2-, and 3-year OS values were 61.9%, 37.9%, and 31.2% and were 38.3%, 23.3%, and 16.0% (P < 0.001), respectively. After the PSM, the median survival time was 16.6 versus 8.6 months (P < 0.002) in the two groups. A subgroup analysis revealed that thrombocytopenia is associated with improved OS in those with type I PVTT (P = 0.021) or type II PVTT (P = 0.029).
According to the PSM, preoperative thrombocytopenia predicts an increased RFS and OS in HCC patients with PVTT after hepatectomy.
门静脉癌栓(PVTT)预示着肝细胞癌(HCC)患者预后不良。血小板(PLTs)在 HCC 的进展和转移中起着重要作用。然而,PLTs 与 PVTT 之间的关系尚不清楚。本研究旨在评估血小板计数在 HCC 合并 PVTT 患者肝切除术后预后中的价值。
2002 年 1 月至 2012 年 12 月,对 694 例 HCC 合并 PVTT 患者行肝切除术。根据术前 PLT 水平,将患者分为血小板减少组(PLT<100×10 /L)、正常组和血小板增多组(PLT>300×10 /L)。采用倾向评分匹配(PSM)分析。
在 PSM 之前,与血小板计数正常或血小板增多的患者相比,血小板减少的 HCC 合并 PVTT 患者的无复发生存率(RFS)和总生存率(OS)更长(均 P<0.001)。对于血小板减少组和正常组,1、2、3 年的 RFS 值分别为 30.0%、17.6%和 15.7%和 10.8%、6.6%和 5.8%(P<0.001);1、2、3 年的 OS 值分别为 61.9%、37.9%和 31.2%和 38.3%、23.3%和 16.0%(P<0.001)。PSM 后,两组中位生存时间分别为 16.6 个月和 8.6 个月(P<0.002)。亚组分析显示,血小板减少与 I 型 PVTT(P=0.021)或 II 型 PVTT(P=0.029)患者的 OS 改善相关。
根据 PSM,术前血小板减少预示着 HCC 合并 PVTT 患者肝切除术后 RFS 和 OS 的提高。